SCHEMBL1493282

SCHEMBL1493282

COc1cc(/C=C/C(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 1.00
CYP1A2 P05177 2/20 1.00
ALOX5 P09917 2/20 1.00
NFKB1 P19838 2/20 1.00
HSD11B1 P28845 2/20 1.00
STAT3 P40763 2/20 1.00
NFKB2 Q00653 2/20 1.00
RELA Q04206 2/20 1.00
NFE2L2 Q16236 2/20 1.00
APP P05067 3/20 0.79
KDM4E B2RXH2 2/20 0.79
CA12 O43570 2/20 0.79
CA1 P00915 2/20 0.79
CA2 P00918 2/20 0.79
CA3 P07451 2/20 0.79
PKM P14618 2/20 0.79
CA4 P22748 2/20 0.79
CA6 P23280 2/20 0.79
CA5A P35218 2/20 0.79
SNCA P37840 2/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1493283 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL30668505 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL29478095 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL19824721 0.95 CYP2D6 (0.91) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL2744233 0.95 CYP2D6 (0.91) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL2744234 0.95 CYP2D6 (0.91) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL15147249 0.94 CYP2D6 (0.88) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL15288997 0.94 CYP2D6 (0.88) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL17019805 0.94 CYP2D6 (0.88) CYP2D6CYP1A2ALOX5NFKB1HSD11B1
SCHEMBL5598747 0.92 CYP2D6 (0.85) CYP2D6CYP1A2ALOX5NFKB1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054365-B1 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES UNIBAN UNIVERSIDADE BANDEIRANTE DE S O PAULO (BR) 2014-09-24 EP claimed
EP-1572614-B1 METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO (BR) 2013-12-25 EP claimed
US-20100048957-A1 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S H L 2010-02-25 US claimed
US-20100029763-A1 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES UNIVERSIDADE BANDEIRANTE DE SAO PAULO-ACADEMIA, PAULISTA ANCHIETA S/C LTDA (BR) 2010-02-04 US claimed
US-7432401-B2 Method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties Fundação de Amparo a Pesquisa Do Estado de São Paulo (BR) 2008-10-07 US claimed
US-20060128997-A1 New method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO (BR) 2006-06-15 US claimed
EP-1572614-A2 NEW METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE AND DERIVATIVES WITH ANTITUMORAL PROPERTIES Fundacio de Amparo Pesquisa do Estado des Sao Paulo (BR) 2005-09-14 EP claimed
WO-2004047716-A2 NEW METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE AND DERIVATIVES WITH ANTITUMORAL PROPERTIES Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) 2004-06-10 WO claimed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
US-20240158430-A1 NOVEL COMPOUND OR SALT THEREOF, AND ANTITUMOR ACTIVATOR CONTAINING SAME AS ACTIVE INGREDIENT AKITA UNIVERSITY (JP) 2024-05-16 US disclosed
WO-2022190915-A1 NOVEL COMPOUND OR SALT THEREOF, AND ANTITUMOR ACTIVATOR CONTAINING SAME AS ACTIVE INGREDIENT 国立大学法人秋田大学 2022-09-15 WO disclosed
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2022-05-19 US disclosed
US-11319273-B2 Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia HOWARD UNIVERSITY (US) 2022-05-03 US disclosed
WO-2004047716-A3 NEW METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE AND DERIVATIVES WITH ANTITUMORAL PROPERTIES FUNDACAO DE AMPARO A PESQUISA (BR) 2004-08-19 WO disclosed
WO-2004047716-A2 NEW METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE AND DERIVATIVES WITH ANTITUMORAL PROPERTIES Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) 2004-06-10 WO disclosed
WO-2004047716-A2 NEW METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE AND DERIVATIVES WITH ANTITUMORAL PROPERTIES Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) 2004-06-10 WO disclosed
JP-2001048756-A HAIR GROWER KANEBO LTD 2001-02-20 JP disclosed
US-6043334-A USEFUL FOR PRODUCTION OF CROSSLINKED POLYCARBONATE RESINS; ELECTROPHOTOGRAPHIC PHOTORECEPTORS, WHICH HAVE PHOTOSENSITIVE LAYER CONTAINING CROSSLINKED POLYCARBONATE RESINS IDEMITSU KOSAN CO., LTD. (JP) 2000-03-28 US disclosed
EP-0866083-A1 POLYCARBONATE RESIN, CROSSLINKED POLYCARBONATE RESIN AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR IDEMITSU KOSAN COMPANY LIMITED (JP) 1998-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158430-A1 NOVEL COMPOUND OR SALT THEREOF, AND ANTITUMOR ACTIVATOR CONTAINING SAME AS ACTIVE INGREDIENT STAT3, STAT6, HDAC1 CYP2D6 4844/4885CYP1A2 4831/4885ALOX5 566/4885
US-20060128997-A1 New method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties DDB1, ANXA1, ANXA5 CYP2D6 1648/4885CYP1A2 2477/4885ALOX5 819/4885
US-11319273-B2 Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia BACE1, GAA, GLA CYP2D6 1912/4885CYP1A2 1886/4885ALOX5 1209/4885
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN CYP2D6 2367/4885CYP1A2 2166/4885ALOX5 1897/4885
US-20100029763-A1 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES CASP3, CYP8B1, DERA CYP2D6 26/4885CYP1A2 71/4885ALOX5 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.